Research groups
Yama F Mujadidi
BCA Computer Application , MSc in Information Technology and Software Engineering
Programming and Data Management Director
Automation and Semantic Interoperability in Clinical Trials
Yama F Mujadidi is the Programming and Data Management Director at the Oxford Vaccine Group. In this role, he provides strategic leadership across the Group’s global portfolio of clinical research, with responsibility for data governance, IT infrastructure, programming, and data management systems.
With more than a decade of experience in clinical trials data management and software engineering, he has led the development and validation of electronic data capture systems (MHRA/GxP/FDA compliant), large-scale database infrastructures, and large language models. His expertise spans information governance, clinical trial regulations, and project management, underpinned by a proven ability to lead multidisciplinary technical teams.
Since joining the Oxford Vaccine Group in 2013, Yama has contributed to major international vaccine trials, trained and mentored research teams in the UK and globally, and co-authored numerous publications in high-impact journals. He has also taken a leading role in advancing novel approaches to clinical trial database design and semantic interoperability.
His achievements have been recognised through several awards, including the Fazlur Rahman Khan Award for Excellence in Engineering and Science (2013), the Association for Clinical Data Management’s Individual Excellence Award (2024), and recognition as Best Muslim in STEM by British Muslim (2024).
Beyond Oxford, Yama is an entrepreneur and founder of organisations advancing educational and technological innovation for global health. He is currently pursuing a DPhil at the University of Oxford on automation and semantic interoperability in clinical trials. Alongside his academic and professional commitments, he serves as a delegate with UN Women UK, advocating for the rights of women and children.
Recent publications
Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial.
Journal article
Kelly E. et al, (2026), J Infect, 92
Preliminary safety data from a randomised trial of early versus standard timing of administration of measles-rubella vaccine in Ugandan infants
Journal article
Businge GB. et al, (2025)
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.
Journal article
Janani L. et al, (2025), J Infect, 91
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
Journal article
Li G. et al, (2025), Vaccine, 62
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.
Journal article
Amini A. et al, (2025), Sci Immunol, 10
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.
Journal article
Costa Clemens SA. et al, (2025), Mayo Clin Proc Innov Qual Outcomes, 9
Interplay between the gut microbiome and typhoid fever: insights from endemic countries and a controlled human infection model.
Journal article
Ashton PM. et al, (2025), Microbiome, 13
Precision Data Management: Using REDCap and Large Language Models to Optimise Clinical Trial Efficiency
Preprint
Mujadidi YF. et al, (2025)
Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa.
Journal article
Chanda C. et al, (2025), Lancet Microbe, 6
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
Journal article
Feng S. et al, (2025), J Infect, 90
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
Journal article
Conlin K. et al, (2025), Vaccine, 45
Five-Year Vaccine Protection Following a Single Dose of Vi-Tetanus Toxoid Conjugate Vaccine in Bangladeshi Children: A Cluster Randomised Trial
Journal article
Qadri F. et al, (2024)
5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
Journal article
Qadri F. et al, (2024), Lancet, 404, 1419 - 1429
Pathogen diversity and antimicrobial resistance transmission of Salmonella enterica serovars Typhi and Paratyphi A in Bangladesh, Nepal, and Malawi: a genomic epidemiological study.
Journal article
Dyson ZA. et al, (2024), Lancet Microbe, 5
Modelling Salmonella Typhi in high-density urban Blantyre neighbourhood, Malawi, using point pattern methods.
Journal article
Khaki JJ. et al, (2024), Sci Rep, 14
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.
Journal article
Jackson S. et al, (2024), Lancet Microbe, 5, 655 - 668
Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.
Journal article
Bijukchhe SM. et al, (2024), Vaccine, 42, 2018 - 2025
Evaluating the relationship between ciprofloxacin prescription and non-susceptibility in Salmonella Typhi in Blantyre, Malawi: an observational study.
Journal article
Ashton PM. et al, (2024), Lancet Microbe, 5, e226 - e234
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial.
Journal article
Hill M. et al, (2023), BMJ Open, 13
SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood.
Journal article
Lugar M. et al, (2023), JAMA, 330, 1151 - 1160
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Journal article
Kelly E. et al, (2023), J Infect, 87, 230 - 241
Direct inference and control of genetic population structure from RNA sequencing data.
Journal article
Fachrul M. et al, (2023), Commun Biol, 6
Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) - a protocol for two parallel, open-label, randomised controlled trials.
Journal article
Kelly S. et al, (2023), Trials, 24
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Journal article
Liu X. et al, (2023), J Infect, 87, 18 - 26
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Journal article
Shaw RH. et al, (2023), J Infect, 86, 574 - 583
Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.
Journal article
Khanam F. et al, (2023), Vaccine, 41, 3137 - 3140
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
Journal article
Liu X. et al, (2023), J Infect, 86, 540 - 541
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Journal article
Voysey M. et al, (2023), Clin Exp Immunol, 211, 280 - 287
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Journal article
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209